AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04936477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calculation of ventilation-perfusion ratio
Description: Three to five paired measurements of fraction of inspired oxygen and peripheral oxygen saturations.~Insertion of mainstream capnograph with combined pressure and flow sensor to perform end-tidal capnography measurement.~Echocardiogram to assess intra-cardiac shunting.
Study NCT02544477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow Nasal Cannula Oxygen (HFNCO)
Study NCT02544477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional oxygen treatment
Study NCT02104297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: deksmedetomidine
Description: deksmedetomidine infused during operation 0.2 mcg/kg/hour
Study NCT02104297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil infused during operation 0.2 mcg/kg/min
Study NCT02104297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: During operation saline infused equal volüme of deksmedetomidine and remifentanil
Study NCT00259402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)
Description: OXALIPLATIN 60 mg/m2/d, CISPLATIN 55 mg/m2/d, 5-FU 600 mg/m2/d with dose range and followed by radiotherapy
Study NCT02559895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALD403
Study NCT02559895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01447940 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Meos ePortal use
Description: Patients will use Meos ePortal + 2 standard visits (inclusion and 12 months) + additional visits if necessary + HbA1c measure at 6 months
Study NCT01447940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Meos ePortal use
Description: Patients will use Meos ePortal + 2 standard visits (inclusion and 12 months) + additional visits if necessary + HbA1c measure at 6 months
Study NCT02712905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB059872
Description: Initial cohort dose of INCB059872 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose(s) will be taken forward into expansion cohorts.~INCB059872 tablets to be administered by mouth.
Study NCT02712905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid (ATRA)
Study NCT02712905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Study NCT02712905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Study NCT05808777 — intervention group
Intervention type: OTHER
Intervention: Phone interview
Description: A interview follow-up with a physician by phone was performed at 12 months after the onset of ICH.
Study NCT01445600 — intervention group
Intervention type: DRUG
Intervention: ALTARGO(retapamulin)
Description: Basically there is no treatment allocation. Subjects who would be administered of ALTARGO(retapamulin) at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study NCT03683823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention guidance
Description: Explicitly guiding attention towards faces during public speaking exposures
Study NCT03683823 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: Public speaking exposures
Study NCT00656097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CL184
Description: CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
Study NCT00656097 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HRIG
Description: HRIG 20 IU/kg intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
Study NCT00656097 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching CL184
Description: Placebo intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
Study NCT04237870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active cTBS
Description: Active cTBS treatment will be delivered at an intensity that is 70% of the resting motor threshold (RMT). cTBS consist of bursts of 3 magnetic pulses at 30 Hz repeating every 200 ms for 300 pulses. cTBS will be repeated twice with 15 min interval. The cTBS sessions last for 4 weeks, 5 times a week. Treatment will be applied to central suleus.
Study NCT04237870 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
Study NCT02770417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: beta-alanine
Description: Patients receive beta-alanine
Study NCT02770417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients receive placebo
Study NCT02770417 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: Healthy controls will be assessed to compare baseline muscle carnosine levels
Study NCT05010239 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 30-minute Mindfulness-Based Supportive Therapy
Description: The MBST consists of a session that involves interviewing patients with open-ended questions on suffering experiences. During the session, the practitioner will practice mindful breathing simultaneously while listening to patients. The practitioner will acknowledge the distress of patients when it is appropriate, but without losing their attention on mindful breathing.
Study NCT05010239 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 30-minute supportive listening
Description: Patients in the control group will receive a 30-minute supportive listening session by a palliative care physician who has no experience in mindfulness practice. The session involves interviewing patients with the same open-ended questions on suffering experiences. The practitioner will acknowledge the distress of patients when it is appropriate. Outcomes will be measured at baseline and at minute 30.
Study NCT02877888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoride varnish 22600ppm
Description: topical application on teeth every 6months
Study NCT01540864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP404
Description: Administered orally once daily for 26 weeks
Study NCT01540864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally once daily for 26 weeks
Study NCT01307657 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: high fat meal
Description: Clopidogrel 600 mg loading dose at 8 am and high-fat meal at 12 pm
Study NCT01781078 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment
Study NCT01781078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImageReady System implant
Description: Pacemaker and lead(s) implant
Study NCT03588559 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Pressure Measurement
Description: Measurement blood pressure by Transtek BPM TMB-1591-A-002 and reference device.
Study NCT01541098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized Plasma
Description: Licensed plasma that has been lyophilized.
Study NCT01541098 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Plasma
Description: Plasma that has been authorized for transfusion.
Study NCT01420887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Passive Motion
Description: Continuous passive motion.
Study NCT01420887 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy.
Study NCT04839952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles
Description: 12 telehealth sessions. The first 5 visits include psycho/medical education plus a motivational interviewing component. The second 7 sessions include psycho/medical education plus a problem solving training component.
Study NCT04839952 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education-Only Control
Description: This control condition includes meeting with a clinician for one telehealth visit to review nutrition and physical activity recommendations.
Study NCT02079480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986090
Study NCT02079480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986090
Study NCT02079480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keyhole limpet hemocyanin
Study NCT04094168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEL NIDO CARDIOPLEGIA
Description: Del Nido components: Plasmalyte 148 (1000 ml), NaHCO3 8.4% 1M (13 ml), MgSO4 0,5 M (16,5 ml), Mannitol 20% (16,3 ml), KCl 2 M (13 ml), Lidocaine 2% (6,5 ml).~Electrolytic composition (l000 ml): Na+ 153 mEq, K+ 31 mEq, Cl - 124 mEq, Mg2+ 19,5 mEq, NaHCO3 13 mEq, Acetate 27 mEq, Sulfate 16,5 mEq, Gluconate 23 mEq.
Study NCT04094168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COLD BLOOD BASED CARDIOPLEGIA
Description: Cardibraun components: Electrolytic composition (1000 ml): Na+ 185,8 mmol, K+ 24,1 mmol, Cl- 192,8 mmol, Acetate 23 mmol, Fosfate 0,97 mmol, Citrate 6,32 mmol.
Study NCT02111317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral
Study NCT02111317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verapamil
Description: oral
Study NCT00003489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Advanced Head and Neck Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT02866630 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Six additional blood samples will be taken from in-situ catheters during heart surgery
Study NCT02457988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivify Kit
Description: home telemonitoring devices with vital sign capturing capabilities, i.e. blood pressure, weight, pulse, and specific questionnaires targeted to the cirrhosis diagnosis.
Study NCT01081132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Guanfacine Hydrochloride
Description: The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on weight.
Study NCT01081132 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be provided as 1,2,3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on weight.
Study NCT02019667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGS-742
Study NCT02019667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01935973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01935973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01935973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trametinib
Description: Given PO
Study NCT01935973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT01935973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprosertib
Description: Given PO
Study NCT04425304 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group counseling
Description: 4 times
Study NCT04425304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group counseling
Description: 4 times
Study NCT04425304 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive group counseling
Description: 14 times
Study NCT04425304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive group counseling
Description: 14 times
Study NCT04425304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Persuasive ICT support
Description: Weekly reminders for 12 months
Study NCT03893669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP607
Description: 1 dose, 0.5ml, Intramuscular (IM) injection
Study NCT03893669 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Agrippal
Description: 1 dose, 0.5ml, Intramuscular (IM) injection
Study NCT00728494 — intervention group
Intervention type: BIOLOGICAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: Peginterferon alfa-2b will be administered according to the product's labeling.
Study NCT00728494 — intervention group
Intervention type: DRUG
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Ribavirin will be administered according to the product's labeling.
Study NCT00728494 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient Assistance Program
Description: The patient assistance program includes the following:~* Training by physicians or specialized nurses.~* Informational materials based on the To beat HCV program.~* Management of specific side effects.
Study NCT00914147 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: pulmonary function testing
Description: After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization.
Study NCT04100616 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study NCT01861067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LESS-TLH
Study NCT01861067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LESS-LAVH
Study NCT02539069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chondron Implantation
Description: In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
Study NCT02731196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Early versus later stabilization and neurodynamic exercise intervention following a post-op lumbar microdiscectomy
Study NCT02731196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Early versus later stabilization and neurodynamic exercise intervention following a post-op lumbar microdiscectomy
Study NCT01963702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxol
Study NCT01963702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Study NCT01963702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT01963702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Study NCT03826017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Catechin high contain greentea extract
Description: Catechin high contain greentea extract 260 mg/day for 12 weeks.
Study NCT03826017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks.
Study NCT01719250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Given PO
Study NCT01719250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01719250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02271113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271
Study NCT02271113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02271113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Sodium (Lovenox®)
Study NCT02256098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATTUNE™ Knee Prosthesis by DePuy
Description: Total Knee Replacement (TKR) Surgery with ATTUNE™ Knee Prosthesis by DePuy
Study NCT02256098 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFC Sigma Knee Prosthesis by DePuy
Description: Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
Study NCT05704816 — intervention group
Intervention type: OTHER
Intervention: Spinal anesthesia application
Description: The success of the needles with different tip designs and thicknesses used in spinal anesthesia application
Study NCT04345276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir+Ritonavir
Description: Danoprevir 100mg , one tablet each time , twice per day, up to 10 days. Ritonavir 100mg, one tablet each time , twice per day, up to 10 days.
Study NCT01559662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugared Chewing Gum (Juicy Fruit)
Description: One stick of gum, 3 times daily from Postoperative day 1 to 7
Study NCT03717597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).~Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity.
Study NCT02280252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (including Abraxane), 30 mg/m2 twice per week. Paclitaxel will be given IV over 1 hour, Abraxane® will be administered over 30 min, and administered on a Monday/Thursday or Tuesday/Friday schedule.
Study NCT02280252 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Patients will receive a total dose of 45 Gy to the breast, axilla and supraclavicular area at 1.8 Gy/fraction, +14 Gy to the original palpable tumor at 2 Gy/fraction (total 32 fractions)
Study NCT02035566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehome Care Monitoring
Description: Telehome care monitoring over a 60-day period wherein patients transmit health measurements to their health care professional on a daily basis
Study NCT04630743 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive and Behavioral intervention for the Management of Episodic Breathlessness
Description: The cognitive and behavioral brief intervention comprises two parts: In a first module, the intervention and the study team is introduced, the definition of episodic breathlessness is given and the individual characteristics of breathlessness episodes are recorded. Goals of the intervention are discussed. In a subsequent module on patient education and the strategies, the patient and intervention executor discuss the patients' assumptions about episodic breathlessness including triggers and already used management strategies for breathlessness episodes. This follows the presentation of the non-pharmacological strategies: movement of air/ handheld fan, forward lean, diaphragmatic breathing, distraction, pursed lips breathing, long breaths out and relaxation training. The patient selects 2-3 strategies and trains them with the intervention executor.
Study NCT04825665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous force
Description: A buccally directed continuous tipping force of 150 g is applied to the maxillary first premolar by a cantilever spring made of 0.017 x 0.025 beta-titanium-molybdenum alloy inserted in the tube of the upper first molar, bypassing the second premolar and attaching to the upper first premolar. The buccal tipping force will be checked and reactivated to the original level on the 28th day of the 8 week study period.
Study NCT04825665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent force
Description: A buccally directed tipping force of 150 g is applied to the maxillary first premolar by a cantilever spring made of 0.017 x 0.025 beta-titanium-molybdenum alloy inserted in the tube of the upper first molar and attaching to the upper first premolar. The buccal tipping force will be removed every 21 days for a 7-day rest period, where a passive wire of the same gauge and material of the cantilever spring (0.017 x 0.025 beta-titanium-molybdenum alloy) will be placed instead to maintain the position of the upper first premolar during the rest period.